The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of one or more colchicine derivatives:
[EN] COMPOUND OF 5- OR 6-MEMBERED HETEROCYCLIC PYRIMIDINES AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRIMIDINES HÉTÉROCYCLIQUES À 5 OU 6 CHAÎNONS ET SON UTILISATION<br/>[ZH] 五元或六元杂环并嘧啶类化合物及其用途
Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS<br/>[FR] DÉRIVÉS D'OXOPYRIDINE UTILES EN TANT QU'INHIBITEURS DE LA SEMIALDÉHYDE DÉCARBOXYLASE D'AMINOCARBOXYMUCONATE (ACMSD)
申请人:MITOBRIDGE INC
公开号:WO2018125983A8
公开(公告)日:2019-06-13
OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS
申请人:Mitobridge, Inc.
公开号:US20210094916A1
公开(公告)日:2021-04-01
The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase